Marseille Cedex 09, France Clinical Trials

A listing of Marseille Cedex 09, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 42 clinical trials
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Hopital La Timone ( Site 3303)
 (1.4 away) Contact site
  • 26 Jun, 2021
  • +52 other locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

epidermal growth factor
Hopital de la Timone
 (1.4 away) Contact site
  • 31 May, 2021
  • +97 other locations
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible. The trial will start …

 (62.6 away) Contact site
  • 24 Jan, 2021
  • +23 other locations
Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy

The liver may not be an optimal site for islet transplantation due to obstacles by an instant blood-mediated inflammatory response, and low revascularization of transplanted islets. Therefore, intramuscular islet transplantation offers an attractive alternative, based on its simplicity, enabling easier access for noninvasive graft imaging and cell explantation.

CHU Rouen
 (469.0 away) Contact site
  • 25 Jan, 2021
  • +4 other locations
VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery

tumor progression
malignant glioma
glioblastoma multiforme
gilbert's syndrome
CHU La Timone
 (1.4 away) Contact site
  • 03 Jul, 2021
  • +3 other locations
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

This is an open label, phase I/II clinical trial to evaluate the efficacy and safety of 2 cycles of durvalumab without (Arm A) or with (Arm B) tremelimumab in association with ddMVAC as neoadjuvant therapy in patients with MIUC.

Institut Paoli Calmettes
 (6.0 away) Contact site
  • 25 Jan, 2021
  • +19 other locations
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.

Institut Paoli-Calmettes
 (1.5 away) Contact site
  • 09 Jul, 2021
  • +4 other locations
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).

induction chemotherapy
secondary acute myeloid leukemia
Institut Paoli-Calmettes
 (1.5 away) Contact site
  • 03 Jun, 2021
  • +40 other locations
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy …

solid tumor
Hospital de la Timone PHASE 2
 (1.4 away) Contact site
  • 05 Feb, 2021
  • +131 other locations
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety …

Research Site
 (1.4 away) Contact site
  • 26 Jul, 2021
  • +24 other locations